Attached files
| file | filename |
|---|---|
| EX-10.1 - AMENDMENT - VITRO DIAGNOSTICS INC | vitro_10ez1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 14, 2017
VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada | 0-17378 | 84-1012042 |
(State or other jurisdiction | Commission File | (I.R.S. Employer Identification number) |
4621 Technology Drive, Golden CO 80403
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 999-2130
______________________________________________________
(Former name or former address, if changed since last report)
___ | Written communications pursuant to Rule 425 under the Securities Act |
___ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
___ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
___ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
ITEM 1.01
ENTRY INTO MATERIAL DEFINITIVE AGREEMENTS
Amendment to Memorandum of Understanding
Effective April 14, 2017, the Board of Directors of Vitro Diagnostics, Inc. (the “Company) approved of an Amendment to a Memorandum of Understanding (“MOU”) between the Company and Caribbean GC Development Fund, Ltd., a Grand Cayman corporation (“Caribbean GC”) (the “Amendment”). A copy of the MOU was previously filed as an exhibit to the Company’s Current Report on Form 8-K dated March 23, 2017 and filed with the Commission on March 29, 2017.
The Amendment extends the closing date of a debt investment as described in the MOU from April 15, 2017 to May 31, 2017. A copy of the Amendment is filed herewith as Exhibit 10.1.
ITEM 9.01: EXHIBITS
Item | Title |
|
|
10.1 | Amendment to Memorandum of Understanding |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| Vitro Diagnostics, Inc. | |
|
|
|
|
| Dated: April 17, 2017 |
| /s/ James R. Musick |
|
|
| James R. Musick, President and Chief Executive Officer |
2